CD4+CD25+ regulatory T cells and their therapeutic potential

被引：94

作者：

Randolph, DA ^{[1
]}

Fathman, CG

机构：

[1] Stanford Univ, Sch Med, Dept Pediat, Div Neonatol, Stanford, CA 94305 USA

[2] Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA

来源：

ANNUAL REVIEW OF MEDICINE | 2006年 / 57卷

关键词：

suppressor T cell; type I diabetes; multiple sclerosis; graft-versus-host disease;

D O I：

10.1146/annurev.med.57.121304.131337

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The human immune system mounts specific responses to a vast array of antigens. Although this is clearly beneficial in fighting off harmful infections and cancerous cells, the system must be carefully controlled to ensure that normal self-antigens are not targeted. A recently characterized subset of T cells, identified by their cell surface expression of CD4 and CD25, is critical in regulating the function of other immune cells and preventing potentially harmful autoimmune responses. This article reviews what is currently known about these so-called regulatory T cells and discusses the therapeutic potential of these cells to modulate human immune-based diseases.

引用

页码：381 / 402

页数：22

共 89 条

[1] Diversity of regulatory CD4+ T cells controlling distinct organ-specific autoimmune diseases [J].

Alyanakian, MA ;

You, S ;

Damotte, D ;

Gouarin, C ;

Esling, A ;

Garcia, C ;

Havouis, S ;

Chatenoud, L ;

Bach, JF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (26) :15806-15811

[2] Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance [J].

Antov, A ;

Yang, L ;

Vig, M ;

Baltimore, D ;

Van Parijs, L .

JOURNAL OF IMMUNOLOGY, 2003, 171 (07) :3435-3441

[3] Origin of regulatory T cells with known specificity for antigen [J].

Apostolou, I ;

Sarukhan, A ;

Klein, L ;

von Boehmer, H .

NATURE IMMUNOLOGY, 2002, 3 (08) :756-763

[4] Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health [J].

Arif, S ;

Tree, TI ;

Astill, TP ;

Tremble, JM ;

Bishop, AJ ;

Dayan, CM ;

Roep, BO ;

Peakman, M .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (03) :451-463

[5] Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation [J].

Asano, M ;

Toda, M ;

Sakaguchi, N ;

Sakaguchi, S .

JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) :387-396

[6] T-regulatory cells: are we re-discovering T suppressors? [J].

Athanassakis, I ;

Vassiliadis, S .

IMMUNOLOGY LETTERS, 2002, 84 (03) :179-183

[7] Interleukin-2: Clinical applications [J].

Atkins, MB .

SEMINARS IN ONCOLOGY, 2002, 29 (03) :12-17

[8] CD4+CD25high regulatory cells in human peripheral blood [J].

Baecher-Allan, C ;

Brown, JA ;

Freeman, GJ ;

Hafler, DA .

JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1245-1253

[9] TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes [J].

Belghith, M ;

Bluestone, JA ;

Barriot, S ;

Mégret, J ;

Bach, JF ;

Chatenoud, L .

NATURE MEDICINE, 2003, 9 (09) :1202-1208

[10] Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells [J].

Bensinger, SJ ;

Walsh, PT ;

Zhang, JD ;

Carroll, M ;

Parsons, R ;

Rathmell, JC ;

Thompson, CB ;

Burchill, MA ;

Farrar, MA ;

Turka, LA .

JOURNAL OF IMMUNOLOGY, 2004, 172 (09) :5287-5296

← 1 2 3 4 5 6 7 8 9 →